An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster Immunization
- Conditions
- Varicella
- Interventions
- Biological: Investigational live attenuated varicella vaccine
- Registration Number
- NCT05150392
- Lead Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.
- Brief Summary
This is an open-labelled clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunity persistence of the single-dose primary immunization of live attenuated varicella vaccine on different time points ,and the safety and immunogenicity after the booster immunization
- Detailed Description
This study is an open-labelled phase Ⅲ clinical trial.The experimental vaccine manufactured by Sinovac(Dalian) Vaccine Technology Co., Ltd.A total of 1195 subjects who received vaccine in the phase Ⅲ lot-consistency clinical trial were be enrolled .All subjects except C0243 and C0556 were divided into 3 groups according to the order of study number.Subjects in 3 groups received a booster immunization of live attenuated varicella vaccines 1 year,2 years and 3 years after primary immunization,respectively.About 3.0ml of venous blood was collected from each enrolled subject at pre-booster immunization,30 days after booster immunization and the serum was separated for neutralizing antibody detection.The antibody levels were used to evaluate the immunity persistence and immunogenicity after booster immunization of live attenuated varicella vaccines .
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1193
- Received one dose live attenuated varicella vaccine in the phase Ⅲ lot-consistency clinical trial;
- Guardian(s) of the volunteer should be capable of understanding the written - consent form, and such form should be signed before the children being included into this study.
- Received one dose live attenuated varicella vaccine at the end of the phase Ⅲ lot-consistency clinical trial;
- According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Booster immunization 2 year after primary immunization Investigational live attenuated varicella vaccine Subjects C0401-C0800 except C0556 received 1 dose of booster immunization 2 years after primary immunization. Booster immunization 1 year after primary immunization Investigational live attenuated varicella vaccine Subjects C0001-C0400 except C0243 received 1 dose of booster immunization 1 year after primary immunization. Booster immunization 3 year after primary immunization Investigational live attenuated varicella vaccine Subjects C0801-C1197 received 1 dose of booster immunization 3 years after primary immunization.
- Primary Outcome Measures
Name Time Method Immunogenicity index-seropositivity rate of antibody 30 days after booster immunization Seropositivity rate of antibody 30 days after booster immunization
Immunogenicity index-seroconversion rate of antibody 3 years after primary immunization seroconversion rates of antibody 3 years after primary immunization
Immunogenicity index-Seroconversion rate of antibody 30 days after booster immunization Seroconversion rate of the neutralizing antibody 30 days after booster immunization
- Secondary Outcome Measures
Name Time Method Immunogenicity index-GMT of the antibody Before the booster dose immunization GMT of the antibody before booster immunization
Immunogenicity index- GMT of the antibody 30 days after booster immunization GMT of the antibody 30 days after booster immunization
Immunogenicity index-Seropositivity rate of antibody Before the booster dose immunization Seropositivity rate of antibody before booster immunization
Immunogenicity index- GMI of the antibody 30 days after booster immunization GMI of the antibody 30 days after booster immunization
Safety index-Incidence of SAE within 30 days after vaccination Incidence of SAE within 30 days after vaccination
Safety index-Incidence of solicited local or systemic AE within 14 days after vaccination Incidence of solicited local or systemic AE within 14 days after vaccination
Safety index-Incidence of local or systemic AE within 30 days after vaccination Incidence of local or systemic AE within 30 days after vaccination
Trial Locations
- Locations (1)
Xiangfu County Center for Disease Control and Prevention
🇨🇳Kaifeng, Henan, China